Beyond one-sizes-fits-all: the promise and pitfalls of stratified medicine in tuberculosis

Tuberculosis remains the leading cause of death from a single infectious disease worldwide, and drug-resistant forms continue to threaten global control efforts.1 Recent years have witnessed a major revolution in the treatment of drug-resistant tuberculosis, with the introduction of several shorter, all-oral regimens. Yet, these approaches remain largely standardized, with little consideration of individual disease characteristics.